For best viewing of the website please use Mozilla Firefox or Google Chrome.
Citation: Malihe Naderi, Atefeh Saeedi, Abdolvahab Moradi, Mishar Kleshadi, Mohammad Reza Zolfaghari, Ali Gorji, Amir Ghaemi. Interleukin-12 as a Genetic Adjuvant Enhances Hepatitis C Virus NS3 DNA Vaccine Immunogenicity [J].VIROLOGICA SINICA, 2013, 28(3) : 167-173.  http://dx.doi.org/10.1007/s12250-013-3291-z

Interleukin-12 as a Genetic Adjuvant Enhances Hepatitis C Virus NS3 DNA Vaccine Immunogenicity

  • Corresponding author: Amir Ghaemi, ghaem_amir@yahoo.com
  • Received Date: 01 November 2012
    Accepted Date: 28 January 2013
    Available online: 01 June 2013
  • Hepatitis C virus (HCV) chronic infection is a worldwide health problem, and numerous efforts have been invested to develop novel vaccines. An efficient vaccine requires broad immune response induction against viral proteins. To achieve this goal, we constructed a DNA vaccine expressing nonstructural 3 (NS3) gene (pcDNA3.1-HCV-NS3) and assessed the immune response in C57BL/6 mice. In this study, the NS3 gene was amplified with a nested-reverse transcriptase-polymerase chain reaction (RT-PCR) method using sera of HCV-infected patients with genotype 1a. The resulting NS3 gene was subcloned into a pcDNA3.1 eukaryotic expression vector, and gene expression was detected by western blot. The resultant DNA vaccine was co-administered with interleukin-12 (IL-12) as an adjuvant to female C57BL/6 mice. After the final immunizations, lymphocyte proliferation, cytotoxicity, and cytokine levels were assessed to measure immune responses. Our data suggest that co-administration of HCV NS3 DNA vaccine with IL-12 induces production of significant levels of both IL-4 and interferon (IFN)-γ (p<0.05). Cytotoxicity and lymphocyte proliferation responses of vaccinated mice were significantly increased compared to control (p<0.05). Collectively, our results demonstrated that co-administration of HCV NS3 and IL-12 displayed strong immunogenicity in a murine model.

  • 加载中
    1. Ahlen G, Nystrom J, Pult I, Frelin L, Hultgren C, and Sallberg M. 2005. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocyte by DNA vaccine-primed cytotoxic T lymphocyte. J Infec Dis, 192(12): 2112-2116.
        doi: 10.1086/jid.2005.192.issue-12

    2. Ahlen G, Söderholm J, Tjelle T, Kjeken R, Frelin L, Höglund U, Blomberg P, Fons M, Mathiesen I, and Sällberg M. 2007. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol, 179(7) : 4741-4753.
        doi: 10.4049/jimmunol.179.7.4741

    3. Andre S, Seed B, Eberle J, Schraut W, Bültmann A, and Haas J. 1998. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol, 72(2): 1497-1503.

    4. Arribillaga L, de Cerio A L, Sarobe P, Casares N, Gorraiz M, Vales A, Bruna-Romero O, Borrás-Cuesta F, Paranhos-Baccala G, Prieto J, Ruiz J, and Lasarte J J. 2002. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV recombinant vaccinia virus. Vaccine, 21: 202-210.
        doi: 10.1016/S0264-410X(02)00456-5

    5. Bartenschlager R, Ahlborn-Laake L, Mous J, and Jacobsen H. 1993. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol, 67: 3835-3844.

    6. Bocher W O, Dekel B, Schwerin W, Geissler M, Hoffmann S, Rohwer A, Arditti F, Cooper A, Bernhard H, Berrebi A, Rose-John S, Shaul Y, Galle P R, F Löhr H, and Reisner Y. 2001. Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. Eur J Immunol, 31: 2071-2079.
        doi: 10.1002/(ISSN)1521-4141

    7. De Francesco R, Tomei L, Altamura S, Summa V, and Migliaccio G. 2003. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA dependent RNA polymerase. J Antiviral Res, 58(1):1-16.
        doi: 10.1016/S0166-3542(03)00028-7

    8. Encke J, zuPutlitz J, Geissler M, and R Wands J. 1998. Genetic Immunization generates cellular and Humoral Immune Responses Against the Nonstructural Proteins of the Hepatitis C Virus in a Murine Model. J Immunol, 1 (61) : 4917-4923.

    9. Feltquate D M, Heaney S, Webster R G, and Robinson H L. 1997. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol. 158: 2278-2284.

    10. Foy E, Li K, Sumpter R, Loo Y M, Johnson C L, Wang C, Fish P M, Yoneyama M, Fujita T, Lemon S M, and Gale M Jr. 2004. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. PNAS, 102 (8): 2986-2991.

    11. Frelin L, Ahlén G, Alheim M, Weiland O, Barnfield C, Liljeström P, and Sällberg M. 2004. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. J Gene Ther, 11(6): 522-533.
        doi: 10.1038/sj.gt.3302184

    12. Frick D N. 2007. The hepatitis C virus NS3 protein: a model RNA helicase andpotential drug target. Curr Issues Mol Biol, 9 (1):1-20.

    13. Gao M, Wang H P, Wang Y N, Zhou Y, and Wang Q L. 2006. HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4+ Th1 cell responses in vivo. Vaccine, 24: 5491-5497.
        doi: 10.1016/j.vaccine.2006.04.004

    14. Geissler M, Gesien A, Tokushige K, and Wands J R. 1997. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine expressing plasmids. J Immunol, 158:1231-1237.

    15. Ghaemi A, Soleimanjahi H, Bamdad T, Soudi S, Arefeian E, Hashemi M, and Ebtekar E. 2007. Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice. J Comp immunol microbiol Infect Dis, 30(4):197-210.
        doi: 10.1016/j.cimid.2007.01.002

    16. Ghaemi A, Soleimanjahi H, Gill P, Zuhair H, Razeghi M, Jahromi S, and Roohvand F. 2010. Recombinant λ-phage nanobioparticles for tumor therapy in mice models. J Genet Vaccines Ther, 8(3): 1-7.

    17. Ghaemi A, Soleimanjahi H, Gill P, Zuhair M H, Razeghi S, Fazeli M, and Razavinikoo S M H. 2009. Protection of Mice by a -Based Therapeutic Vaccine against Cancer Associated with Human Papillomavirus Type 16. J Intervirol, 54:105-112.

    18. Gherardi M M, Ramirez J C, and Esteban M. 2000. Interleukin-12 (IL-12) Enhancement of the Cellular Immune Response against Human Immunodeficiency Virus Type 1 Env Antigen in a DNA Prime/Vaccinia Virus Boost VaccineRegimen Is Time and Dose Dependent: Suppressive Effects of IL-12 Boost Are Mediated by Nitric Oxide. J Virol, 74: 6278-6286.
        doi: 10.1128/JVI.74.14.6278-6286.2000

    19. Guermonprez P, Valladeau J, Zitvogel L, Thery C, and Amigorena S. 2002. Antigen presentation and T cell stimulation by dendritic cells. J Annu Rev Immunol, 20: 621-667.
        doi: 10.1146/annurev.immunol.20.100301.064828

    20. Gurunathan S, Klinman D M, and Seder R A. 2000. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol, 18: 927-974.
        doi: 10.1146/annurev.immunol.18.1.927

    21. Ha S J, Jeon B Y, Kim S C, Kim D J, Song M K, Sung Y C, and Cho S N. 2003. Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with mycobacterium tuberculosis. J Gene Ther, 10: 1543.
        doi: 10.1038/sj.gt.3302042

    22. Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T, Kimura K, and Shimotohno K. 1993. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol, 67: 4665-4675.

    23. Jiao X, Wang R Y, Feng Z, Hu G, Alter H J, and W-K Shih J. DNA immunization encoding the secreted nonstructural protein 3 (NS3) of hepatitis C virus and enhancing the Th1 type immune response. 2004. J Viral Hepatol, 11(1):18-26.
        doi: 10.1046/j.1352-0504.2003.00464.x

    24. Kim J J, Ayyavoo V, Bagarazzi M L, Chattergoon M A, Dang K, Wang B, Boyer J D, and Weiner D B. 1997. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol, 158: 816-826.

    25. Kieper W C, Tan J T, Bondi-Boyd B, Gapin L, Sprent J, Ceredig R, and Surh C D. 2002. Overexpression of interleukin (IL)-7 leads to IL-15-independent generation of memory phenotype CD8+ T cells. J Exp Med, 195: 1533.
        doi: 10.1084/jem.20020067

    26. Kieper W C, Prlic M, Schmidt C S, Mescher M F, and Jameson S C. 2001. Il-12 enhances CD8+ T cell homeostatic expansion. J Immunol, 166: 5515.
        doi: 10.4049/jimmunol.166.9.5515

    27. Koff R S. 2003. Hepatitis vaccines: recent advances. Int J Parasitol, 33: 517-523.
        doi: 10.1016/S0020-7519(03)00065-1

    28. Lanford R E, Guerra B, Chavez D, Bigger C, Brasky K M, Wang X H, Ray S C, and Thomas D L. 2004. Cross-genotype immunity to hepatitis C virus. J Virol, 78(3):1575-1581.
        doi: 10.1128/JVI.78.3.1575-1581.2004

    29. Lang K A, Yan J, Draghia-Akli R, Khan A, and Weiner D B. 2008. Strong HCV NS3-and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine, 26 (49): 6225-6231.
        doi: 10.1016/j.vaccine.2008.07.052

    30. Lauer G M, and Walker B D. 2001. Hepatitis C virus infection. N Engl J Med, 345: 41-52.
        doi: 10.1056/NEJM200107053450107

    31. Martin T. 1999. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther, 10(5):759-768.
        doi: 10.1089/10430349950018517

    32. Nichols W W. 1995. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci, 772: 30-39.
        doi: 10.1111/nyas.1995.772.issue-1

    33. Semmo N, Day C L, Ward S M, Lucas M, Harcourt G, Loughry A, and Klenerman P. 2005. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. J Hepatol, 41 (5): 1019-1102.
        doi: 10.1002/(ISSN)1527-3350

    34. Pang P S, Jankowsky E, Planet P J, and Pyle A M. 2002. The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding. EMBO J, 21: 1168-1176.
        doi: 10.1093/emboj/21.5.1168

    35. Pawlotsky J M. 2009. Hepatitis: HCV variability, the immune system and resistance to antiviral drugs. Nat Rev Gastroenterol Hepatol, 6(7): 383-385.
        doi: 10.1038/nrgastro.2009.102

    36. Schmidt C S, and Mescher M F. 1999. Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD81 T cells in vivo. J Immunol, 163: 2561.

    37. Scott P, and Trinchieri G. 1997. IL-12 as an adjuvant for cell-mediated immunity. Semin J Immunol, 9: 285-291.
        doi: 10.1006/smim.1997.0084

    38. Sin J I, Kim J J, Arnold R L, Shroff K E, McCallus D, Pachuk C, McElhiney S P, Wolf M W, Pompa-de Bruin S J, Higgins T J, Ciccarelli R B, and Weiner D B. 1999. IL-12 Gene as a DNA Vaccine Adjuvant in a Herpes Mouse Model: IL-12 Enhances Th1-Type CD4+ T Cell-Mediated Protective Immunity against Herpes Simplex Virus-2 Challenge. J Immunol, 162: 2912-2921.

    39. Shan M M, Liu K Z, Fang H L, and Chen Z. 2002. DNA immune responses induced by codelivery of IL-12 expression vectors with hepatitis C structural antigen. HBPD INT, 1(4): 553-557.

    40. Tokushige K, Wakita T, Pachuk C, Moradpour D, Wener D B, Zurawski J R V R, and Wands J R. 1996. Expression and Immune Response to Hepatitis C Virus Core DNA-Based Vaccine Constructs. J Hepatol, 24:14-20.
        doi: 10.1002/(ISSN)1527-3350

    41. Weck K. 2005. Molecular methods of hepatitis C genotyping. Expert Rev Mol Diagn, 5 (4): 507-520.
        doi: 10.1586/14737159.5.4.507

    42. Weiner A J, Paliard X, Selby M J, Medina-Selby A, Coit D, Nguyen S, Kansopon Joe, L Arian Ch, Ng Ph, Tucker Jeffery, Lee Ch-T, K Polakos N, Han J, Wong Sh, Lu H-H, Rosenberg S, M Brasky K, Chien D, Kuo G, and Houghton M. 2001. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol, 75(15): 7142-7148.
        doi: 10.1128/JVI.75.15.7142-7148.2001

    43. Xiang Z, and Ertl H C. 1995. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. J Immunity, 2: 129-135.
        doi: 10.1016/S1074-7613(95)80001-8

    44. Yang S H, Lee C G, Park S H, Im S J, Kim Y M, Son J M, Wang J S, Yoon S K, Song M K, Ambrozaitis A, Kharchenko N, Yun Y D, Kim C M, Kim C Y, Lee S H, Kim B M, Kim W B, and Sung Y C. 2006. Correlation of antiviral Tcell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. J Gene Ther, 13(14): 1110-1117.
        doi: 10.1038/sj.gt.3302751

  • 加载中

Figures(3)

Article Metrics

Article views(3350) PDF downloads(3) Cited by()

Related
Proportional views
    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Interleukin-12 as a Genetic Adjuvant Enhances Hepatitis C Virus NS3 DNA Vaccine Immunogenicity

      Corresponding author: Amir Ghaemi, ghaem_amir@yahoo.com
    • Department of Microbiology, Qom branch, Islamic Azad University, Qom 37185-364, Iran
    • Department of Microbiology, Lahijan Branch, Islamic Azad University, Lahijan 1616, Iran
    • Golestan Research Center of Gastroenterology and Hepatology-GRCGH, Department of Microbiology, Golestan
    • Shefa Neuroscience Research Centre, Tehran 1996835911, Iran
    • Institut für Physiologie I, Westfälische Wilhelms-Universität Münster, Robert-Koch-Strasse Münster 48149, Germany
    • Klinik und Poliklinik für Neurochirurgie, Westfälische Wilhelms-Universität Münster, Münster 48149, Germany

    Abstract: Hepatitis C virus (HCV) chronic infection is a worldwide health problem, and numerous efforts have been invested to develop novel vaccines. An efficient vaccine requires broad immune response induction against viral proteins. To achieve this goal, we constructed a DNA vaccine expressing nonstructural 3 (NS3) gene (pcDNA3.1-HCV-NS3) and assessed the immune response in C57BL/6 mice. In this study, the NS3 gene was amplified with a nested-reverse transcriptase-polymerase chain reaction (RT-PCR) method using sera of HCV-infected patients with genotype 1a. The resulting NS3 gene was subcloned into a pcDNA3.1 eukaryotic expression vector, and gene expression was detected by western blot. The resultant DNA vaccine was co-administered with interleukin-12 (IL-12) as an adjuvant to female C57BL/6 mice. After the final immunizations, lymphocyte proliferation, cytotoxicity, and cytokine levels were assessed to measure immune responses. Our data suggest that co-administration of HCV NS3 DNA vaccine with IL-12 induces production of significant levels of both IL-4 and interferon (IFN)-γ (p<0.05). Cytotoxicity and lymphocyte proliferation responses of vaccinated mice were significantly increased compared to control (p<0.05). Collectively, our results demonstrated that co-administration of HCV NS3 and IL-12 displayed strong immunogenicity in a murine model.